source
- U.S. proposes rule tightening review of biotech licensing deals with Chinese firmsThe U.S. is preparing to issue a proposed rule that would place additional scrutiny on outbound licensing agreements between American biotech firms and Chinese companies. The measure aims to increa…
- Menarini's Stemline signs $1.1 billion deal to license Georgiamune's preclinical cancer immunotherapyGeorgiamune, a Maryland‑based immunology biotech, has granted Stemline Therapeutics, part of Italy's Menarini Group, exclusive worldwide rights to develop and commercialize its preclinical cancer c…